2022 White Paper on Recent Issues in Bioanalysis: Fda Draft Guidance on Immunogenicity Information in Prescription Drug Labeling, Lnp & Viral Vectors Therapeutics/Vaccines Immunogenicity, Prolongation Effect, Ada Affinity, Risk-Based Approaches, Ngs, Qpcr, Ddpcr Assays ( <u>Part 3</u> – Recommendations on Gene Therapy, Cell Therapy, Vaccines Immunogenicity & Technologies; Immunogenicity & Risk Assessment of Biotherapeutics and Novel Modalities; NAb Assays Integrated Approach)Luying Pan, Swati Gupta, Francis Dessy et al.|Bioanalysis|2023Cited by 15
Comparison of Pre-existing Anti-AAV8 Total Antibody Screening and Confirmatory Assays with a Cell-Based Neutralizing Assay in Normal Human SerumYan‐Shan Dai, Vibha Jawa, Huijin Dong et al.|The AAPS Journal|2023Cited by 12
Bioanalytical Methods for Characterization of <scp>CAR‐T</scp> Cellular Kinetics: Comparison of <scp>PCR</scp> Assays and MatricesMadhan Masilamani, Sekhar Surapaneni, Vibha Jawa et al.|Clinical Pharmacology & Therapeutics|2023Cited by 12
Immunogenicity Risk Assessment of Process-Related Impurities in An Engineered T Cell Receptor Cellular ProductJohanna Mora, Chloé Ackaert, Daron Forman et al.|Journal of Pharmaceutical Sciences|2024Cited by 3